menu
    • menu
    [{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"||Adrenergic receptor alpha-1","graph1":"Urology","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"MSN Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Sawai Pharmaceutical Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Sawai Pharmaceutical Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sawai Pharmaceutical Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sawai Pharmaceutical Co \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"MALTA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Tablet, Modified Release","sponsorNew":"Adalvo \/ Adamed Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adamed Pharma"},{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"Hikma Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genuine Research Center, Egypt \/ Hikma Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Genuine Research Center, Egypt \/ Hikma Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Solifenacin Succinate

    Menu

    Solifenacin Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adalvo

                            Malta arrow
                            Formnext Forum
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate,Tamsulosin

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Adamed Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe

                            Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.

                            Product Name : Vesomni-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : Solifenacin Succinate,Tamsulosin

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Adamed Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genuine Research Center, Egypt

                            Country arrow
                            Formnext Forum
                            Not Confirmed

                            Genuine Research Center, Egypt

                            Country arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Hikma Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 14, 2023

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Hikma Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aurobindo Pharma Limited

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Aurobindo Pharma Limited

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aurobindo Receives FDA Approval for Solifenacin Succinate Tablets, 5mg and 10mg

                            Details : Solifenacin succinate is a muscarinic 3 receptor antagonist which works to decrease bladder activity by inhibiting contraction of the smooth muscle wall surrounding the bladder.

                            Product Name : VESIcare-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 01, 2023

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Camber Pharmaceuticals Launches Generic Vesicare®

                            Details : Solifenacin Succinate, an oral tablet, and generic version of Vesicare, a muscarinic antagonist, is launched to treat symptoms of overactive bladder, such as frequent or urgent urination, and incontinence (urine leakage).

                            Product Name : Vesicare-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 28, 2022

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cipla

                            India arrow
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tamsulosin,Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CDSCO Panel Gives Nod for FDC Tamsulosin + Solifenacin

                            Details : Solifenacin is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 12, 2022

                            Lead Product(s) : Tamsulosin,Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MSN Laboratories

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            MSN Laboratories

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate,Mirabegron

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSN Laboratories Gets CDSCO Panel Nod For FDCs Solifenacin, Mirabegron Capsules

                            Details : Solifenacin succinatei immediate release tablet is a muscarinic receptor antagonist and Mirabegron capsule is a potent and selective β3-adrenoceptor agonist, indicated for the treatment of overactive bladder.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 30, 2022

                            Lead Product(s) : Solifenacin Succinate,Mirabegron

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sawai Pharmaceutical Co

                            Japan arrow
                            Formnext Forum
                            Not Confirmed

                            Sawai Pharmaceutical Co

                            Japan arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths

                            Details : Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

                            Product Name : VESIcare-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2021

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zydus Lifesciences

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Cadila Receives USFDA Final Approval for Solifenacin Succinate Tablets

                            Details : Solifenacin succinate is a muscarinic 3 receptor antagonist which works to decrease bladder activity by inhibiting contraction of the smooth muscle wall surrounding the bladder.

                            Product Name : Vesicare-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 20, 2020

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Astellas Pharma

                            Japan arrow
                            Formnext Forum
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients

                            Details : VESIcare LS is an oral suspension dosage form that was specifically developed to facilitate dosing and administration in the pediatric population.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 27, 2020

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Astellas Pharma

                            Japan arrow
                            Formnext Forum
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Reproducibility Study of OABSS and Its Response to Treatment

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 29, 2016

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth